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Abstract: Kisspeptin has been implicated in cardiovascular control. Eicosanoids play a crucial role in the activation of platelets
and the regulation of vascular tone. In the present study, we investigated the effect of kisspeptins on eicosanoid synthesis in
platelets and aorta in vitro. Platelets and aorta were isolated fromWistar–Kyoto rats. After preincubation with different doses of
kisspeptin, samples were incubated with [1-14C]arachidonic acid (0.172 pmol/mL) in tissue culture Medium 199. The amount of
labeled eicosanoids was measured with liquid scintillation, after separation with overpressure thin-layer chromatography.
Kisspeptin-13 stimulated the thromboxane synthesis. The dose–response curve was bell-shaped and the most effective concen-
tration was 2.5 × 10−8mol/L, inducing a 27% increase. Lipoxygenase products of platelets displayed a dose-dependent elevation up
to the dose of 5 × 10−8mol/L. In the aorta, kisspeptin-13 induced amarked elevation in the production of 6-keto-prostaglandin F1,
the stable metabolite of prostacyclin, and lipoxygenase products. Different effects of kisspeptin on cyclooxygenase and
lipoxygenase products indicate that beyond intracellular Ca2+ mobilization, other signaling pathways might also contribute to
its actions. Our data suggest that kisspeptin, through the alteration of eicosanoid synthesis in platelets and aorta, may play a
physiologic and (or) pathologic role in the regulation of vascular tone.
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Résumé : On sait que la kisspeptine agit sur le contrôle des fonctions cardiovasculaires et que les eicosanoïdes jouent un rôle
crucial dans l’activation des plaquettes et la régulation du tonus vasculaire. Dans le cadre de la présente étude, nous avons étudié
in vitro les effets des kisspeptines sur la synthèse des eicosanoïdes dans les plaquettes et dans l’aorte. Les plaquettes et les aortes
de ratsWistar–Kyoto étaient isolées et, après incubation en présence de différentes doses de kisspeptine, les échantillons étaient
incubés en présence d’acide [1-14C]arachidonique (0,172 pmol/mL) dans un milieu de culture M199. Après séparation par chro-
matographie sur couche mince sous pression, nous avons mesuré par scintillation liquide la quantité d’eicosanoïdes marqués.
La kisspeptine-13 a permis de stimuler la synthèse de thromboxane : la courbe dose-réponse, en forme de cloche, indiquait que
la concentration la plus efﬁcace était de 2,5 × 10–8 mol/L pour l’induction d’une augmentation de 27 %. Les produits de la
lipoxygénase plaquettaire ont augmenté de manière proportionnelle a` la dose jusqu’a` 5 × 10–8 mol/L. Dans l’aorte, la
kisspeptine-13 a induit de façon marquée l’augmentation de la production de 6-céto-PGF1 (le métabolite stable de la prostacy-
cline) et des produits de la lipoxygénase. Les effets différentiels de la kisspeptine sur la cyclo-oxygénase et les produits de la
lipoxygénase laissent penser qu’en plus de lamobilisation duCa2+ intracellulaire, d’autres voies de signalisation pourraient aussi
contribuer a` son action. Nos données laissent entendre que la kisspeptine pourrait jouer un rôle physiologique et (ou)
pathologique dans la régulation du tonus vasculaire en altérant la synthèse des eicosanoïdes dans les plaquettes et dans l’aorte.
[Traduit par la Rédaction]
Mots-clés : kisspeptine, plaquettes, aorte, eicosanoïdes.
Introduction
Approximately 30 years ago, the tetrapeptide FMRFamide was
isolated from the ganglia of clam as a cardioexcitatory peptide
(Price and Greenberg 1977). Since then, a number of RF-amide
peptides have been identiﬁed that all share the Arg-Phe motif at
the C-terminal. They possess a wide range of effects that include
regulation of vascular tone and cardiac function (Fukusumi et al.
2006).
KP, a member of the RF-amide family, is the product of the Kiss1
gene (Tena-Sempere 2013). The prepropeptide, consisting of 145
amino acids, is cleaved to produce a C-terminally aminated 54
amino acid peptide, KP-54. As a result of alternative splicing, other
biologically active derivatives are produced, e.g., KP-14, KP-13, and
KP-10 (Tena-Sempere 2013). KPs are one of the main regulators of
the reproductive axis; however, by binding to their cognate recep-
tor, GPR54, and by activating the Gq/11, the ERK1/2, and the p38
MAP kinase signaling pathways (Castaño et al. 2009), they might
play a role in several other processes.
Furthermore, KPs bind to NPFF receptors (Lyubimov et al. 2010;
Elhabazi et al. 2013), the ligand of which (NPFF) has already been
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reported to cause hypertension and tachycardia, both of which
seem to be due to the interaction of peripheral NPFF receptors and
adrenergic receptors (Allard et al. 1995). This suggests that KP
might have an effect on the cardiovascular system. The expression
and possible function of KP has been investigated in the cardio-
vascular center in the brain, in the heart, and in various vessel
types (Maguire et al. 2011). Evidence showed the presence of the KP
system in atherosclerosis-prone vessels (Mead et al. 2007) and in
edema formation (Sawyer et al. 2011), the latter of which was
antagonized by COX inhibition. A recent publication reported
that KP has anticoagulant activity, which might be mediated
through changes in Ca signaling, consequently leading to a de-
creased thrombin concentration and platelet number (Qureshi
and Kanwal 2011).
Platelets serve as an important link among inﬂammation,
thrombosis, and atherogenesis. The active products of the intact
endothelium (e.g., prostacyclin and nitric oxide) can inhibit plate-
let and leukocyte adhesion to the vascular surface andmaintain a
balance between prothrombotic and antithrombotic activity (Hadi
and Suwaidi 2007). Inﬂammation is ampliﬁed by the interactions
among platelets, leukocytes, and endothelial cells. These inter-
plays can trigger autocrine and paracrine activation that lead to
leukocyte recruitment into the vascular wall. Consequently, a
platelet-induced chronic inﬂammatory process at the vascular
wall results in the development of atherosclerotic lesions and
atherothrombosis (Gawaz et al. 2005). One of the most important
regulators of these processes are lipid mediators. The octade-
canoids, eicosanoids, and docosanoids, synthesized from the
appropriate polyunsaturated fatty acids, play an important role
in the regulation of cell (e.g., platelets, leukocytes, endothelial
cells, vascular smooth muscle cells) functions under physio-
logic or pathologic conditions. The eicosanoids are the metab-
olites of AA released from the membrane phospholipids by
phospholipase A2. Three classes of enzymes are responsible for me-
tabolizing AA: COXs, LOXs, and cytochrome P450 monooxygenases.
Activation of the COX pathway leads to the formation of prosta-
glandins and prostacyclin, the LOX pathway produces the HETEs,
and the cytochrome P450 monooxygenase pathway synthesizes
the epoxyeicosatrienoic acids. Several cell types engage in AA
metabolism, through which different classes of eicosanoids are
assembled consequently targeting a variety of cells (Eritsland
2000; Bogatcheva et al. 2005; Russo 2009; Raphael and Sordillo
2013), and thus eicosanoids play a crucial role in platelet activa-
tion and regulation of vascular tone (Sellers and Stallone 2008;
Félétou et al. 2010). The effects of KP on vasculature and platelets
have already been investigated (Mead et al. 2007; Maguire et al.
2011; Qureshi and Kanwal 2011).
On the basis of previous ﬁndings in the literature, it may be
hypothesized that eicosanoids mediate the effects of KP on the
vasculature and platelets. Therefore, in the present study, we
aimed to investigate the effect of KP-13, a biologically active form
of KP that binds to both GPR54 and NPFF receptors (Elhabazi et al.
2013), on eicosanoid synthesis in platelets and aorta under resting
condition in vitro.
Methods
Chemicals
[14C]AA (speciﬁc activity: 2035 MBq/mmol) was from Amersham
(England). Serum-free tissue culture Medium 199 was purchased
from Sigma (St. Louis, Missouri, USA). Silica gel thin-layer plates
(0.25 mm) were obtained from Merck AG (Darmstadt, Germany).
AA (grade 1), 12-HHT, and 12-HETE, used as unlabeled standards,
were purchased from Sigma (St. Louis, Missouri, USA). KP-13 was
purchased from Bachem (Bubendorf, Switzerland). PGE2, PGD2,
TxB2, PGF2, and 6-kPGF1 were generously provided by Upjohn
Co. (Kalamazoo, Michigan, USA).
Animals
Adult male Wistar–Kyoto rats, weighing 210–230 g (n = 6), were
used. The animals were maintained on 12 h dark : 12 h light cycles
in a room at constant temperature (23 ± 1 °C) with access to stan-
dard laboratory food and water ad libitum. Animal experiments
were performed under a protocol accepted by the Ethical Com-
mittee for the Protection of Animals in Research at the University
of Szeged, Hungary. All experiments were carried out in accor-
dance with the Guide for the Care and Use of Laboratory Animals pub-
lished by the US National Institutes of Health.
Isolation of platelets
Under ether anesthesia, blood was drawn from the abdominal
aorta of rats and diluted (1:2) with phosphate buffer (pH 7.4) con-
taining EDTA (5.8 mmol/L) and glucose (5.55 mmol/L). PRP was
collected after the whole blood had been centrifuged at 200g for
10 min at room temperature. Platelets were separated from the
supernatant by centrifugation at 2000g for 10 min, and the pellet
was used for further separation. Since the contaminating red blood
cells could metabolize AA via the LOX pathway and release leuko-
trienes (Kobayashi and Levine 1983), the erythrocytes were lysed
with hyposmic ammonium chloride (0.83%, 9 parts) containing
EDTA (0.02%, 1 part) at 4 °C for 15 min. The platelets were then
washed with phosphate buffer (pH 7.4, containing 5.8 mmol/L
EDTA and 5.55 mmol/L glucose) and centrifuged at 2000g for
10 min at room temperature. During the separation procedure,
platelet activation was inhibited by using a Ca2+-free medium and
siliconized glassware. The washed platelet suspension was free
from other cellular elements of the blood (red blood cells, leuko-
cytes, etc.) and plasma proteins. After the last centrifugation,
platelets were resuspended (2 × 108 platelets/mL) in serum-free
Medium 199 tissue culture.
Isolation of the abdominal aorta
Under ether anesthesia, after taking blood from rats, the ab-
dominal aorta was isolated. The fat and connective tissue was
removed from the aorta, which was then sliced into 1–2 mm rings
with care to not damage the endothelium.
Analysis of eicosanoids
Platelets (2 × 108 cells/mL in each sample) were preincubated in
the presence of different concentrations of KP-13 (0, 1 × 10−8, 2.5 ×
10−8, 5 × 10−8, 7.5 × 10−8, and 1 × 10−7 mol/L) at 37 °C for 5min, while
the aorta rings (15 mg wet mass/mL in each sample) were pre-
incubated for 10 min in tissue culture Medium 199. The applied
concentrations of KP were based on previous in vitro studies
investigating KP’s effect on different cell lines (Kotani et al. 2001;
Taylor et al. 2014).
The enzyme reaction was started by pipetting the tracer sub-
strate [14C]AA (3.7 kBq, 0.172 pmol/mL in each sample) into the
incubation mixture. Ten minutes later in platelets, and 30 min
later in aorta samples, the enzyme reaction was stopped by bring-
ing the pH to 3 with formic acid. The samples were then extracted
twice with 3 L of ethyl acetate and the organic phases were
pooled and evaporated to dryness under nitrogen. The residues
were reconstituted twice in 100 mL of ethyl acetate and quantita-
tively applied to silica gel G thin-layer plates. The plates were
developed to a distance of 16 cm in the organic phase of ethyl
acetate – acetic acid – 2,2,4-trimethylpentane – water (110:20:30:
100) by means of OPTLC (Chrompres 25, Labor MIM, Hungary)
(Abdel-Halim et al. 1980; Cryer 2009). Each 3 mm band of the
chromatograms was then scraped off and the radioactivity was
determined with a liquid scintillation analyzer (TRI-CARB 2100TR,
Canberra Packard,USA), using 5mLof toluene containing0.44% (m/v)
2,5-diphenyloxazole, 0.02% (m/v) 1,4-di-[2-(5-phenyl)oxazoyl]benzene,
and 10% (v/v) ethanol. Radioactivity was expressed in disintegrations
per minute (dpm). The radio-labeled products of AA were identiﬁed
withunlabeled authentic standards (Kiefer et al. 1975), i.e., 6-kPGF1
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(Rf = 0.21) and HETEs in one peak (Rf = 0.71), which were detected
with anisaldehyde reagent (Mezei et al. 2000). Assuming that the
exogenously administered [14C]AA, as a tracer, is converted in the
same way as the endogenous source, our method allows measure-
ment of the relative amounts of various prostanoids.
Statistical analysis
The results are expressed as means ± SE. The signiﬁcance of the
differences between the eicosanoid syntheses of the KP-treated
and the control platelets were evaluated by one way analysis of
variance (ANOVA), followed by Tukey’s multiple comparison post
hoc test. A difference at a P level of <0.05 was considered statisti-
cally signiﬁcant. The statistical analysis was performed by Sigma-
Plot version 11 (Systat Software, California, USA).
Results
The total amount of COX metabolites (6-kPGF1, PGF2, TxB2,
PGE2, PGD2, and 12-HHT) synthesized by rat platelets was signiﬁ-
cantly elevated by 2.5 × 10−8 mol/L KP-13, from 22 068 ± 2 669 to
29 343 ± 1 800 dpm. The investigation of the effects of the differ-
ent doses of KP-13 on the COX metabolites production showed a
bell-shaped form (Fig. 1).
In our experiments, the synthesis of TxB2 in platelets was stim-
ulated by KP-13. The dose–response curve showed a bell-shaped
correlation, and the most effective KP-13 concentration was 2.5 ×
10−8 mol/L, inducing an increase in production of TxB2 from
6934 ± 617 to 9415 ± 276 dpm (Fig. 2). No signiﬁcant changes were
detected for the other COX metabolites.
LOX products of platelets also showed a dose-dependent eleva-
tion (from 39 605 ± 4 553 to 52 284 ± 5 331 dpm) up to a dose of 5 ×
10−8 mol/L KP, beyond which further stimulation was not possible
(Fig. 1).
In the aorta, the production of 6-kPGF1 was increased signiﬁ-
cantly when 5 × 10−8 mol/L KP-13 was applied (Fig. 3). The total
amount of COX metabolites (6-kPGF1, PGF2, TxB2, PGE2, PGD2,
and 12-HHT) synthesized by rat aorta showed only a slight eleva-
Fig. 1. The effect of kisspeptin-13 (KP) on the synthesis of platelet cyclooxygenase and lipoxygenase metabolites. Data are the means ± SE of
6 samples/animals, in disintegrations per minute (dpm). *, indicates a statistically signiﬁcant difference compared with the untreated, control
samples at P < 0.05.
Fig. 2. The effect of kisspeptin-13 (KP) on the synthesis of platelet thromboxane B2. Data are the means ± SE of 6 samples/animals, in
disintegrations per minute (dpm). *, indicates a statistically signiﬁcant difference compared with the untreated, control samples at
P < 0.05.
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tion in response to KP that did not prove to be signiﬁcant (not
shown on the ﬁgure). On the other hand, 5 × 10−8mol/L dose of KP-13
elicited a marked increase in the amount of LOX metabolites.
Discussion
In the present experiments, KP-13 stimulated both the COX and
LOX pathways in platelets; however, the dose–response curves
showed different characteristics. A KP dose of 2.5 × 10−8 mol/L
caused a signiﬁcant elevation in the amount of COX metabolites.
However, further increasing the dose failed to increase COX pro-
duction, rather a bell-shaped response was observed. Only a
higher dose of KP was able to signiﬁcantly stimulate the amount
of LOX metabolites, and the dose–response curve showed a pla-
teau when using higher doses. Furthermore, in platelet suspen-
sion, KP signiﬁcantly increased the synthesis of TxB2. TxB2 is the
stable metabolite of TxA2, which is the main vasoconstrictor and
platelet activator COX metabolite of platelets (Kurahashi et al.
2003; Norel 2007; Félétou et al. 2010). KP causes an elevation of
intracellular Ca2+ concentration,which generally stimulates phos-
pholipase A2 and consequently leads to the activation of the
whole arachidonate cascade, both the COX and the LOX pathways
(Bonventre 1992; Chawengsub et al. 2009). Therefore, KP might
exert its effects on the arachidonate metabolites through en-
hanced Ca2+ signaling (Castaño et al. 2009). However, the different
pattern of COX and LOX pathway activation indicates that beyond
increasing intracellular Ca2+ concentration, other signaling path-
ways, such as the ERK1/2 and the p38 MAP kinase, may also play a
role (Castaño et al. 2009). In fact, literature suggests a link be-
tween the p38 MAP kinase pathway and LOX activation (Reddy
et al. 2002).
Our results demonstrate that KP activates the arachidonate cas-
cade not only in platelets but also in aorta slices. However, the
pattern of metabolite production in aorta slices was different
from that in platelets. KP produced a marked increase in the
amount of the 6-kPGF1, the stablemetabolite of prostacyclin that
exerts vasodilator and platelet inhibitory effect, and only a mod-
erate increase in the total COXmetabolites. This may suggest that
the increased 6-kPGF1 takes up the majority of the changes
displayed in the total COX metabolites. On the other hand, KP
induced a signiﬁcant elevation in the concentration of LOX
metabolites in the aorta. It is also worth mentioning that the
dose–response curve in the aorta for all metabolites was bell-
shaped and the same dose of KP evoked maximal changes in COX
and LOX metabolites. Clearly, the different pattern of metabolite
release in platelets and vessels can cause different end-effects as
well. Metabolites released from platelets would probably result in
vasoconstriction mediated mainly by TxA2 release. On the other
hand, KP induces the synthesis of LOX products and PGI2, which
might mediate relaxation of the vasculature. Our results seem
contradictory; however, taken together with the conﬂicted data
on this matter in the literature, it is possible that KP’s action
might be cell or tissue type-dependent and site-dependent
(Kurahashi et al. 2003; Mead et al. 2007; Maguire et al. 2011; Sawyer
et al. 2011). Therefore, the different receptor expression patterns,
different signaling pathways, and the availability of different en-
zymes could well justify our results. Also, KP can act through
multiple intracellular signaling pathways (Castaño et al. 2009)
that may contribute to its effect. On the basis of our results, KP
through themodiﬁcation of eicosanoid synthesismay be involved
in physiologic regulation of vascular tone and might inﬂuence
pathologic conditions such as the inﬂammatory reaction and the
course of hemostatic processes. It must be noted, however, that in
our experiments, we investigated KP’s effect on platelets and
aorta isolated fromhealthy animals. Moreover, eicosanoid synthe-
sis was assessed under resting conditions. All care was taken to
prevent platelet activation during the experiment: no vasocon-
strictors or platelet activators were applied. Also, the amount of
the labeled arachidonic acidwas only a fraction (pmol/mL) of what
is required for aggregation (mol/mL), and plastic tubes and in-
struments as well as EDTA were used throughout separation. The
effects of KP could be mediated by a change in octadecanoid and
docosanoidmetabolism as well. However, the experimental setup
used in this study is not suitable for the detection of these metabo-
lites. Still, docosanoid production should be limited, since commer-
cial rat pellet contained mainly saturated and n–6 polyunsaturated
fatty acids (Russo 2009).
KP exerts its effects through the activation of 2 receptors,
GPR54 and NPFF receptors (Castaño et al. 2009; Elhabazi et al.
2013). As NPFF receptors have already been implicated in cardio-
vascular control (Allard et al. 1995), it is plausible that KP binding
Fig. 3. The effect of kisspeptin-13 (KP) on the synthesis of 6-keto-prostaglandin F1 (6-kPGF1) and lipoxygenase metabolites in aorta. Data are
the means ± SE of 6 samples/animals, in disintegrations per minute (dpm). *, indicates a statistically signiﬁcant difference compared with the
untreated, control samples at P < 0.05.
Pagination not final (cite DOI) / Pagination provisoire (citer le DOI)
4 Can. J. Physiol. Pharmacol. Vol. 93, 2015
Published by NRC Research Press
Ca
n.
 J.
 P
hy
sio
l. 
Ph
ar
m
ac
ol
. D
ow
nl
oa
de
d 
fro
m
 w
w
w
.n
rc
re
se
ar
ch
pr
es
s.c
om
 b
y 
Sa
n 
D
ie
go
 (U
CS
D)
 on
 09
/01
/15
Fo
r p
er
so
na
l u
se
 o
nl
y.
 
to NPFF receptors takes part, together with the other members of
the RF-amide family, in the regulation of vascular tone (Sellers
and Stallone 2008) and hemostasis (Qureshi Kanwal 2011). It is also
possible that GPR54 binding mediates the effect of KP. Multiple
data available in the literature might support this contention:
ﬁrst, distribution data on the expression of the GPR54 receptor
(Hadi and Suwaidi 2007), and second, sex differences in vascular
wall sensitivity to vasoconstrictor agents (Sellers and Stallone
2008; Nijher et al. 2010).
In conclusion, KP stimulated the COX and LOX metabolite pro-
duction in platelets, however, in a different pattern thanmight be
explained by the diverse intracellular signaling pathways acti-
vated by KP. Furthermore, in the aorta, KP evoked a signiﬁcant
increase in 6-kPGF1 level and in LOXmetabolite production. KP’s
actions on the eicosanoid synthesis of platelets and aorta may
provide another layer of physiologic and (or) pathologic regula-
tion of vascular tone.
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